🏛️ Verified NIH Record • Updated 2026-02-19
A Study of Mosliciguat in PH-ILD (NCT06635850)
A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Pulmovant, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Who can join: Review the eligibility criteria below.
Location: Arizona Pulmonary Specialists — Phoenix, Arizona
Age range: 18 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Arizona Pulmonary Specialists — Phoenix, Arizona
- Ronald Reagan UCLA Medical Center — Los Angeles, California
- University of California Davis School of Medicine — Sacramento, California
- Harbor-UCLA Medical Center - Torrance — Torrance, California
- Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC — Celebration, Florida
- Northwestern University — Chicago, Illinois
- University of Iowa Hospitals and Clinics — Iowa City, Iowa
- University of Kansas Medical Center — Kansas City, Kansas
- Norton Pulmonary Specialists — Louisville, Kentucky
- Duke University Health System - Duke Clinic — Durham, North Carolina
- PulmonIx — Greensboro, North Carolina
- Hoxworth Blood Center — Cincinnati, Ohio
- Summit Health — Bend, Oregon
- Lewis Katz School of Medicine — Philadelphia, Pennsylvania
- Brown Medicine — East Providence, Rhode Island
- Medical University of South Carolina — Charleston, South Carolina
- Houston Methodist Lung Center — Houston, Texas
- University of Utah Health — Salt Lake City, Utah
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Hypertension
- Trans-pulmonary Biomarkers in Pulmonary Hypertension — Nashville, Tennessee
- Activity Monitoring in Pulmonary Hypertension — Nashville, Tennessee
- LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF — Tucson, Arizona
- A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) — Phoenix, Arizona
- Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD — San Francisco, California
Explore by condition: All Pulmonary Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.